RT Journal Article
T1 Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19.
A1 Buxeda, Anna
A1 Arias-Cabrales, Carlos
A1 Pérez-Sáez, María José
A1 Cacho, Judit
A1 Cabello Pelegrin, Sheila
A1 Melilli, Edoardo
A1 Aladrén, María José
A1 Galeano, Cristina
A1 Lorenzo, Inmaculada
A1 Mazuecos, Auxiliadora
A1 Saura, Isabel María
A1 Franco, Antonio
A1 Ruiz-Fuentes, María Del Carmen
A1 Sánchez-Cámara, Luis Alberto
A1 Siverio, Orlando
A1 Martin, María Luisa
A1 González-García, Elena
A1 López, Verónica
A1 Martin-Moreno, Paloma Leticia
A1 Moina, Iñigo
A1 Moral Berrio, Esperanza
A1 Moreso, Francesc
A1 Portolés, José María
A1 Santana-Estupiñán, Raquel
A1 Zárraga, Sofía
A1 Canal, Cristina
A1 Sánchez-Álvarez, Emilio
A1 Pascual, Julio
A1 Crespo, Marta
K1 SARS-CoV2l
K1 acute kidney injury
K1 immunosuppression
K1 kidney transplantation
K1 remdesivir
AB Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
YR 2021
FD 2021-07-06
LK http://hdl.handle.net/10668/18190
UL http://hdl.handle.net/10668/18190
LA en
DS RISalud
RD Apr 11, 2025